A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ADMINISTRATION OF A PHOSPHODIESTERASE 5 INHIBITOR (PF-00489791) IN ADULTS WITH TYPE 2 DIABETES AND OVERT NEPHROPATHY
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ADMINISTRATION OF A PHOSPHODIESTERASE 5 INHIBITOR (PF-00489791) IN ADULTS WITH TYPE 2 DIABETES AND OVERT NEPHROPATHY
PF-00489791 is an inhibitor of phosphodiesterase type 5. Our hypothesis is that PF-00489791 will enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.
Inclusion Criteria:
Exclusion Criteria:
Azusa, California 91702, United States
Lincoln, Nebraska 68510, United States
Greenfield Park, Quebec J4V 2H1, Canada
Copenhagen Oe, 2100, Denmark
Pokfulam, Hong Kong
Pokfulam, Hong Kong
Hyderabad, Andhra Pradesh 500096, India
Tlalpan, Mexico City 14000, Mexico
San Luis Potosà City, San Luis Potosà 78240, Mexico
Angeles Del Pedregal Cp., 10700, Mexico
Belgrade, 11 000, Serbia
Houghton, Johannesburg, 2198, South Africa